 Myeloablative Agonists
"Myeloablative Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
| Descriptor ID |
D019653
|
| MeSH Number(s) |
D27.505.696.477.656.750 D27.505.954.248.589
|
| Concept/Terms |
Myeloablative Agonists- Myeloablative Agonists
- Agonists, Myeloablative
- Myeloablative Agonist
- Agonist, Myeloablative
|
Below are MeSH descriptors whose meaning is more general than "Myeloablative Agonists".
Below are MeSH descriptors whose meaning is more specific than "Myeloablative Agonists".
This graph shows the total number of publications written about "Myeloablative Agonists" by people in UAMS Profiles by year, and whether "Myeloablative Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 2 | 0 | 2 | | 2017 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2015 | 1 | 1 | 2 | | 2014 | 1 | 1 | 2 | | 2013 | 0 | 1 | 1 | | 2012 | 2 | 0 | 2 | | 2011 | 0 | 1 | 1 | | 2010 | 1 | 1 | 2 | | 2008 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Myeloablative Agonists" by people in Profiles over the past ten years.
-
Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5.
-
Mizuno K, Dong M, Fukuda T, Chandra S, Mehta PA, McConnell S, Anaissie EJ, Vinks AA. Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. Clin Pharmacokinet. 2018 05; 57(5):625-636.
-
Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Peter Gale R, Lazarus HM, Ustun C, Copelan E, Ky Hamilton B, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry CG, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ. Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biol Blood Marrow Transplant. 2018 05; 24(5):945-955.
-
Katragadda L, McCullough LM, Dai Y, Hsu J, Byrne M, Hiemenz J, May S, Cogle CR, Norkin M, Brown RA, Wingard JR, Chang M, Moreb JS. Effect of melphalan 140?mg/m(2) vs 200?mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience. Clin Transplant. 2016 08; 30(8):894-900.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|